Table of Contents

1. PROSTATE CANCER SUSCEPTIBILITY GENES 2. INTRODUCTION AND HISTORY OF PSA SCREENING 3. PROSTATE SPECIFIC ANTIGEN AND OTHER KALLIKREINS IN PROSTATE CANCER 4. PROSTATE CANCER SCREENING AND EARLY TREATMENT: THE ONLY POSSIBILITY FOR A MAJOR IMPACT ON SURVIVAL IN PROSTATE CANCER. 5. MAGNETIC RESONANCE IMAGING AND SPECTROSCOPIC IMAGING OF PROSTATE CANCER: IMPROVED THERAPEUTIC SELECTION AND ASSESSMENT. 6. MOLECULAR STAGING IN CLINICALLY LOCALIZED AND ADVANCED PROSTATE CANCER. 7. BONE MICROENVIRONMENT PARTICIPATION IN THE DEVELOPMENT OF ANDROGEN ABLATION REFRACTORINESS IN PROSTATE CANCER PATIENTS WITH BONE METASTASES: CLINICAL APPLICATION OF AN ANTI-SURVIVAL FACTOR THERAPY. 8. COMBINED ANDROGEN BLOCKADE WITH NON-STEROIDAL ANTI-ANDROGENS FOR ADVANCED PROSTATE CANCER: A REVIEW OF THE EVIDENCE ON EFFICACY AND TOXICITY. 9. PATHOLOGIC CHANGES INDUCED BY HORMONE THERAPY IN NORMAL PROSTATE CARCINOMA 10. STATUS OF ANDROGEN BLOCKADE IN PROSTATE CANCER IN 2003 11. STRATEGIES FOR PROSTATE CANCER PREVENTION. REFERENCES

About the Author

Fernand Labrie MD, Ph.D Laval University Hospital, Research Centre Canada Michael Koutislieris MD, Ph.D Department of Experimental Physiology, Medical School, University of Athens, Athens